Ocumetics Technology Corp. announced that its Group One clinical trial patients for a new accommodating intraocular lens have reached the 12-month follow-up milestone, showing continued vision improvement and safety. Patients reported enhanced ability to read, watch TV, recognize family, and perform daily activities, with one previously legally blind patient regaining vision sufficient to drive. These results support further clinical development and regulatory progress. The company is preparing for the next trial phase to evaluate safety and vision performance more extensively.
Ocumetics clinical trial progress is the subject, here is Pluang's Health-sector market snapshot as of Sep 17, 2026 19:42 WIB: Out of 91 priced US Health-sector stocks, 74 rose and 15 fell today. Notable movers include CRSP at USD 53.31 with a 1-day change of +2.11% and a Pluang order activity of 35% Sell / 65% Buy, OSCR at USD 33.02 with a 1-day change of +2.10% and 0% Sell / 100% Buy order activity, and TLRY at USD 4.01 with a 1-day change of +2.04%. Typical hold times on Pluang range from 14 to 76 days for these stocks.
Fluence Energy's stock price target was cut sharply from $15.00 to $4.00 by RBC Capital analyst Christopher Dendrinos after the company slashed its 2026 revenue forecast from $3.00 billion to $2.40 billion. The company now expects an adjusted EBITDA ...
Regency Centers reported solid Q2 2026 results with Funds From Operations (FFO) at $1.21 per share and a 3.8% growth in same-property Net Operating Income (NOI). The company raised its full-year guidance, signaling confidence in continued growth. Reg...
Ciena reported a 37% revenue increase to $1.67 billion and a 215% rise in adjusted EPS to $2.11 in its fiscal third quarter, driven by strong demand from AI and cloud infrastructure. The company is well positioned to benefit from the AI networking ma...
Maureen Gellerman, Chief Human Resources Officer at Five Below, sold 1,610 shares of the company, generating $401,000 from the transaction. This insider sale may indicate personal financial planning or portfolio rebalancing but does not necessarily r...
ON Semiconductor is focusing on advanced power-density technologies for AI data centers and electric vehicles, aiming for $2.5 billion revenue from AI alone by 2030. Despite a Neutral rating from UBS, the company introduced its Embedded Power Platfor...
